AU2002220744A1 - T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy - Google Patents

T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy

Info

Publication number
AU2002220744A1
AU2002220744A1 AU2002220744A AU2074402A AU2002220744A1 AU 2002220744 A1 AU2002220744 A1 AU 2002220744A1 AU 2002220744 A AU2002220744 A AU 2002220744A AU 2074402 A AU2074402 A AU 2074402A AU 2002220744 A1 AU2002220744 A1 AU 2002220744A1
Authority
AU
Australia
Prior art keywords
papillomavirus
diagnostics
therapy
protein
cell epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220744A
Inventor
Andreas Kaufmann
John Nieland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigene AG
Original Assignee
Medigene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene AG filed Critical Medigene AG
Publication of AU2002220744A1 publication Critical patent/AU2002220744A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2002220744A 2000-12-01 2001-11-30 T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy Abandoned AU2002220744A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10059631A DE10059631A1 (en) 2000-12-01 2000-12-01 T-cell epitopes of the papillomavirus L1 and E7 proteins and their use in diagnostics and therapy
DE10059631 2000-12-01
PCT/EP2001/014037 WO2002044384A2 (en) 2000-12-01 2001-11-30 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy

Publications (1)

Publication Number Publication Date
AU2002220744A1 true AU2002220744A1 (en) 2002-06-11

Family

ID=7665350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220744A Abandoned AU2002220744A1 (en) 2000-12-01 2001-11-30 T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy

Country Status (7)

Country Link
US (1) US20040091479A1 (en)
EP (1) EP1370661A2 (en)
JP (1) JP2004514449A (en)
AU (1) AU2002220744A1 (en)
CA (1) CA2430526A1 (en)
DE (1) DE10059631A1 (en)
WO (1) WO2002044384A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papilloma virus for use in human t cell response inducing compositions
DE10137102A1 (en) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalent vaccine against diseases caused by papillomaviruses, processes for their production and their use
AU2015213420B2 (en) * 2007-05-31 2017-02-16 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
CA3016942C (en) * 2007-05-31 2022-09-20 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US20120045413A1 (en) * 2010-04-09 2012-02-23 Mayumi Nakagawa Human papilloma virus peptide-specific T-cell response for treatment of warts
WO2013111448A1 (en) * 2012-01-25 2013-08-01 学校法人 久留米大学 Human papilloma virus type 16l1-derived b cell epitope peptide
KR101680567B1 (en) * 2014-07-09 2016-11-29 연세대학교 산학협력단 Use of HPV peptide for diagnostic and treatment of cervical cancer
JP7115803B2 (en) 2016-06-20 2022-08-09 アイエスエー ファーマシューティカルズ ビー．ヴイ． Peptide vaccine formulation
EP4048293A4 (en) * 2019-10-21 2023-12-06 Flaskworks, LLC Systems and methods for cell culturing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803870D0 (en) * 1988-10-28 1988-10-28 Medscand Ab METHOD FOR DETECTION OF HUMAN PAPILLOMAVIRUS (HPV) FOR DIAGNOSTIC PURPOSES
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
SE9501512D0 (en) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for papillomavirus vaccination
DE19925199A1 (en) * 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy

Also Published As

Publication number Publication date
CA2430526A1 (en) 2002-06-06
WO2002044384A2 (en) 2002-06-06
WO2002044384A3 (en) 2003-10-16
DE10059631A1 (en) 2002-07-18
US20040091479A1 (en) 2004-05-13
JP2004514449A (en) 2004-05-20
EP1370661A2 (en) 2003-12-17

Similar Documents

Publication Publication Date Title
AU4244200A (en) Multi-functional therapeutic compress and methods of using the same
AU2001236798A1 (en) Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2001253411A1 (en) Medical dressing assembly and associated method of using the same
AU2001238701A1 (en) Ultrasonic medical device and associated method
AU2001267475A1 (en) Combinations of Enzyme Inhibitor-Containing Preparations and the use thereof
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002219229A1 (en) Means for the diagnosis and therapy of CTCL
AU2001265264A1 (en) Devices and methods for assisting natural heart function
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
AU2002220744A1 (en) T-cell epitope of the papillomavirus L1 and E7 protein and use thereof in diagnostics and therapy
AU2001246909A1 (en) Tube for medical care and method for preparing the same
AU2002234773A1 (en) Pharmaceutically effective ginsenosides and their use
AU2001261375A1 (en) Human caspase-12 materials and methods
AU4014700A (en) Tuberculosis antigens and methods of use therefor
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001249692A1 (en) Phospholipid scramblases and methods of use thereof
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2001296477A1 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
AU2002305811A1 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
AU2001274309A1 (en) Phosphoglycan messengers and their medical uses
AU2001261534A1 (en) The meca-79 antigen and related methods